Immunotherapy drug combination helps extend survival in patients with metastatic melanoma Dr. Kamal Kant Kohli22 Aug 2023 9:45 AM ISTUSA: An immunotherapy drug combination was shown to be an effective second-line therapy for metastatic melanoma, an aggressive and deadly type of...
Setback: Merck, Eisai to stop late-stage study of Keytruda plus Lenvima for metastatic melanoma Ruchika Sharma8 April 2023 2:01 PM ISTThey also said another late-stage trial for Keytruda and Lenvima did not meet its main goal of overall survival for treating a type of colorectal or...
Bristol Myers gets USFDA approval for First LAG-3-Blocking Antibody Combination, Opduala MD Bureau20 March 2022 2:30 PM ISTThe trial met its primary endpoint, progression-free survival, and Opdualag more than doubled the median PFS when compared to nivolumab monotherapy,...
FDA declines expanded approval for Bristol-Myers' Opdivo drug Pooja Bhatia Bhatia28 Nov 2015 9:56 AM ISTBristol-Myers Squibb Co said the U.S. Food and Drug Administration declined to approve its immuno-oncology drug, Opdivo, for its expanded use to treat...
Novartis gets FDA approval for skin cancer drug combination savita thakur thakur23 Nov 2015 5:14 PM ISTNovartis AG said on Friday it received the U.S. Food and Drug Administration's regular approval for a drug combination to treat an aggressive form of...
